Scientists at the University of California, San Francisco, have reported that an experimental cancer therapy completely eliminated diffuse midline glioma, an aggressive and almost always fatal childhood brain cancer, in every mouse tested across two disease models. The treatment uses engineered immune cells, designated B-SYNC CAR-T cells, which are designed to remain inactive in the body until they reach the brain. Once there, the cells switch on and attack the tumor. DMG typically kills patients within a year of diagnosis, and effective treatments have remained elusive.
The approach addresses a central challenge in brain cancer therapy: delivering potent immune attacks to tumors without causing widespread damage elsewhere in the body. By confining activation to the brain microenvironment, the researchers aim to improve safety while maintaining efficacy. The findings, published following preclinical testing, showed complete tumor elimination in both mouse models studied. While the results are described as a significant proof of concept, the therapy has not yet been evaluated in human clinical trials. Further research will be required to determine whether the approach translates safely and effectively to pediatric patients.
Independent reporting synthesized from primary wires and global correspondents.